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Abstract  
Introduction: the burden of disease represented by snakebites is widely underestimated and often neglected public health problem in the tropics. 
There is insufficient epidemiological data to guide distribution of antivenin and proper management of venomous snakebites. We describe the 
presentation, management and outcome of snakebites in two district hospitals in Ghana. Methods: using data collection sheet, we prospectively 
documented information on all snakebite victims presenting at two Ghanaian district hospitals from 1st January 2011 to 31st December 2011. 
Results: 163 snakebites representing incidence of 92/100,000 were recorded with mean age of 24 (16SD) years. 62.0% were males and 41.7% 
were farmers. Most bites occurred in April (14.3%), June (12.4%) and November (12.4%) and had occurred when victims were involved in farm-
related activities (50.3%). Average time of presentation after snakebite was 3.6 (1.0 SD) hours and commonest clinical presentations were pain 
(93.0%), swelling (84.0%) and bleeding (51%). Of the total cases 76.7% were given antivenon, 96.3% were given antibiotics, 91.4% 
corticosteroids and 58.3% antihistamines. No mortality was recorded. Conclusion: provision of protocols and their strict adherence in the 
management of snakebites is required to limit unwarranted use of antibiotics and steroids in the management of snakebite. We recommend 
evaluation of all antivenins imported for management of snakebites to ascertain their effectiveness so as to reduce morbidity and mortality 
associated with snakebites in this region. 
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Introduction 
 
The burden of disease caused by snakebites is a widely 
underestimated and often neglected problem in Sub-Saharan Africa 
[1]. This region alone reports an estimated snake envenomations of 
10,001 to 100,000 with an incidence of 8.9-93.3/100,000 persons 
per year and an estimated 1001 to 10,000 deaths representing a 
mortality rate of 0.5-5.9/100,000 persons per year [2]. Snakebites 
also cause significant morbidity from direct venom effects such as 
hemolysis, neurotoxicity, and severe tissue damage, as well as 
primary or secondary infections at the bite site [3].  
  
In Ghana, the saw-scaled viper Echis ocellatus is a commonly found 
species responsible for the majority of snake envenomation. Most 
bites occur among rural and farming populations who are exposed 
to the vipers during agricultural activities. Bites of this species carry 
relatively high morbidity and mortality due to local tissue necrosis as 
well as systemic coagulopathies induced by the venom [4]. Anti-
venom such as the FAV-Afrique polyvalent anti-venom (Avenits 
Pasteur) has been used effectively in the treatment of Echis bites 
[5]. Unfortunately, the supply of effective anti-venom within and 
outside the health system is often unreliable, or its therapeutic use 
is too costly for many victims to access [6].  
  
As a result, effective anti-venom may often be substituted by 
cheaper, less effective ones [7,8]. A more comprehensive 
understanding of the local epidemiologic, social, and clinical aspects 
surrounding snakebites and envenomation can help policy makers 
and front line health professionals design appropriate strategies to 
improve prevention and management of these injuries, and reduce 
snakebite morbidity and mortality. In order to add to the currently 
available knowledge, we undertook a case series study in two 
districts of Ghana located in the forest-savanna transition belt. Our 
data examine and describe the presentation of snakebite cases, the 
clinical management of the victims, and the treatment outcomes.  
  
  
Methods 
 
The study was conducted in the Kintampo North Municipality in the 
Brong-Ahafo Region and the Bole District in the Northern Region of 
Ghana. Figure 1 is a map Ghana showing the Kintampo north and 
Bole districts.The vast parts of each of the two districts are 
essentially rural and characterized by subsistence farming. Each 
district has one hospital which serves as the main referral health 
facility for a number of rural health centers. Common snakebites 
documented in these hospitals in previous years include vipers, 
cobras, pythons, adders and black mambas.  
  
This study included a prospective documentation of snakebite cases 
presenting to the two hospitals in the period between January and 
December 2012. We collected detailed quantitative information on 
the sociodemographic background of the victims, the exposure and 
circumstances associated with the bite, the pre-hospital care 
received by the victim, as well as the clinical presentation and 
treatment outcomes during hospital stay. A specifically-designed 
questionnaire was administered to victims or close relations after a 
patient’s initial presentation to the hospital. We supplemented this 
primary data with clinical information from the medical records of 
the victims. Health care providers who participated in data collection 
at the two hospitals were doctors and physician assistants. These 
were trained in using the data collection sheets, and instructed to 
notify a member of the study team each time a snakebite victim was 
admitted, to follow-up the case and update the questionnaire form 
accordingly until the patient’s discharge or death. We defined 
snakebites as patients who saw the snake and claimed to have been 
bitten, or if the patient sustained a definite fang marks and snake 
was seen or not by the patient, or if patient had clinical evidence of 
snakebite and snake was seen but no fan marks were identified.  
  
We used EPI-DATA (version 2.2) for data entry into a digital 
database. Data analysis using descriptive statistics was done using 
STATA version 12. Ethical approval for the study was obtained from 
the institutional review boards of the Kintampo Health Research 
Center, the Ghana Health Service, and the Columbia University, New 
York.  
  
  
Results 
 
One hundred and sixty-three of the snakebite cases (82 in Bole and 
81 in Kintampo) were reported during the 12-month study period. 
This gives a facility-based incidence of 110/100,000 population in 
Bole and 74/100,000 population in Kintampo, and an overall 
incidence of 92/100,000 population. Table 1 shows the socio-
demographic characteristic snakebite victims. Snakebite victims 
were generally young with a mean age of 24(16SD) years.  
  
The majority were men (62.0%). Male victims were generally 
younger (20.3,13.6SD years) compared to females(30.3,17.6SD 
years). The youngest patient was a two yearsold boy who was in 
the company of older siblings hunting while in the bush. The oldest 
patient was a 92 female farmer who was bitten on the right leg 
while working on the farm. Only about 47% of the victims had any 
form of education with less than 1% going beyond secondary 
education. Most victims were farmers (41.7%) or students (33.1 
%). The highest number of snakebite cases were recorded during 
the months of April (14.3%), June (12.4%) and November (12.4%). 
Two thirds (68%) of the bites occurred at night.  
  
Table 2 shows the distribution of snakebite by exposure 
characteristics. Bites occurred most when victims were undertaking 
farming-related activities (50.3 %), other outdoor events (playing 
on the field, hunting for rats) (16.0%), or in-house activities 
(waking up to urinate, sleeping) (13.5%). About 86%% of bites 
occurred at the extremities with lower limb involvement constituting 
almost 73%. In cases where the snake was seen (58.3%), the 
majority (75.9%) could not describe the color. The most common 
colors of snake that were reported were black in 17 cases, black and 
white in 2 cases, and green in 1 case. Victims or other individuals 
present at the scene identified the 17 ‘black’ snakes as cobras. In 12 
cases, victims/bystanders reported that vipers were involved, which 
they identified by their local names (i.e. Akwatia and Kyereben). All 
victims reported to the hospital more than one hour after the 
snakebite. Average time of presentation after the snakebite was 3.6 
(1.0SD) hours and this did not differ with sex and age of victims. 
The majority (49%) of the patients presented to the emergency 
room between 4-12 hours after snakebite occurred. Only five 
patients reported to the hospital more than 24 hours after being 
exposed to snakebite. Two of these late presenters had received a 
form of herbal medication prior to presentation at the hospital. In 
general, few patients received any form of pre-hospital treatment. 
Pre-hospital treatments that were reported included external 
application of local herbs (35 cases), incision at the site of bite (16 
cases), wound cleaning with water (10 cases), and application of 
tourniquet (6 cases) or ‘black stone’ to the site of bite (5 cases). 
Other traditional remedies included concoctions to swallow (2 cases) 
and application of a starchy fluid from the bark of the pawpaw tree.  
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Table 3 displays the clinical manifestations of snakebites.The most 
frequently encountered clinical presentation was pain at bite site 
(93%), swelling (84%), and local bleeding (51%). Other 
manifestations of envenomation included generalized edema (27%), 
hypotension, hematemesis (12%), dizziness (12%), as well as 
headache, fever, chills, diarrhea, hematemesis, and anuria. 107 
(66.0%) patients showed a prolonged clotting time as measured by 
the whole blood clotting test. Management and outcome of 
snakebite patients is presented in Table 4. A total of 125 cases 
(77%) received snake anti-venom. The majority of patients (61%) 
were given between 2-5 vials of the snake anti-venom; only one 
patient received 12 vials before full recovery was achieved. In 
47.2% of the cases, the snake anti-venom was supplied free of 
charge from the Ghana Health Service through regional medical 
stores, while in 48.8% of the cases the anti-venom was directly 
purchased by the patient from the hospitals’ pharmacies (25.6%) or 
from pharmaceutical shops in town (23.2%). Most patients also 
received antibiotics for infection prophylaxis (96%), corticosteroids 
(91%), and anti-tetanus prophylaxis (74%). Blood transfusions were 
given to 10% of the patients.  
  
Nearly all patients (98%) were admitted to the hospitals. Of these, 
78.4% were successfully treated and discharged, 4% requested for 
discharge against advice from the medical team, while 17.3% were 
referred to a higher level health facilities for reasons such as 
shortage of blood at the hospital, shortage of anti-venom, and 
severe infection requiring advanced care. On average a snakebite 
patient stayed in the hospital for 4.4(1.9SD) days. The length of 
stay did not vary with age or sex of the victim.  
  
  
Discussion 
 
The cumulative incidence of snakebites in our study was 92/100,000 
population. This health facility based estimate is comparable to 
similar findings in sub-Saharan Africa [9,10]. The results may, 
however, grossly underestimate the incidence of snakebites in the 
general population. Victims of snakebites in sub-Saharan Africa may 
self-medicate or seek treatment with traditional healers, and may 
die or recover without ever reaching a health facility [1]. In many 
areas of Africa, the incidence of snakebites estimated from 
household or community based studies is 3-5 times higher as 
compared with health facility based studies [11,12]. The reasons for 
the difference in incidence documented at each of the two sites in 
our study are unclear. The disparity could represent a difference in 
the actual incidence of snakebite, or reflect a difference hospital 
utilization rates in Bole compared to Kintampo. Patients may either 
come from adjacent communities or patients may decide to go to 
another hospital outside of the catchment area [1]. The 
circumstances surrounding snakebite events among patients in both 
of the study sites were largely consistent with known risks. For 
example, global patterns of injury from snakebite suggest that it is 
predominantly an occupational health risk among agricultural 
workers [5], with the highest frequency of bites during months 
devoted to planting and harvest, and a majority of events occurring 
from late afternoon to early evening [13]. Also, snakes tend to hide 
during the day to avoid human activity and tend to be more of a risk 
in darkness when they venture out to look for prey. In our sample, 
most (66.3%) bites occurred in the evenings when the victims were 
engaged in farm related activities or other outdoor ventures. In 
Ghana, the rainy season usually falls between April and September, 
and farmers start preparing their farms for cultivation around April 
and May. Planting occurs in June and harvesting in late October and 
November. A majority of the bites documented in our sample 
occurred during the months of April (14.29%), June (12.42%) and 
November (12.42%), which aligns with the farming activities of this 
mostly agrarian population.  
  
Most of the snakebite victims in our sample were children and 
young adults, which is also in agreement with other reports [6,14, 
15]. The high incidence of snakebites in these segments of the 
population is most likely because children and young adult males 
are those who most often work outdoors in contact with vegetated 
areas. For example, children in rural areas of Africa are commonly 
used as herds’ men. This outdoor exposure coupled with their 
natural curiosity might put them at a higher risk for snakebites [15]. 
About 72% of snakebites in this study involved the lower limbs, 
which is consistent with most epidemiological findings [10,16]. Tan 
reported upper limb bites to be more common, but the majority of 
victims in Tan’s study were soldiers in field training and snake 
catchers whose outdoor activities differ from those of farming [14].  
  
Of note, the zero mortality rate attributable to snakebite in our 
sample was unexpected based on previously published data [1]. 
This finding might represent a selection bias, and is difficult to 
interpret without knowledge of the true incidence and outcomes of 
envenomation in the community. Factors which might have 
influenced patient outcomes in our sample include the pattern of 
help-seeking behavior observed, the identity and toxicity of the 
snakes involved, and therapeutic interventions provided at the 
health centers. Early presentation to a hospital, coupled with 
training of emergency staff in snakebite management protocols and 
adequate supply of anti-venom have been implicated in reducing 
mortality associated with venomous bites in sub-Saharan Africa 
[10]. The average time of presentation following the bite in our 
sample was 3.6 (1.0 SD) hours, which is much earlier than reported 
in previous studies in this part of the region [10], but comparable to 
another study done in Nepal [17]. This would suggest a differing 
health-seeking behavior of the snakebite victims examined in our 
study, and may have been a factor influencing the health outcomes.  
  
Different health seeking behavior in the study population was also 
suggested by the relatively low rates of traditional medicine use and 
pre-hospital self-treatment reported by patients in the study. Only 
21.5% reported any use of herbal medication or application of ‘black 
stone’ to the bite site prior to presentation at the emergency ward. 
Secondary injuries from other common forms of first aid, such as 
tourniquet application or incision and manipulation of the wound, 
were also relatively rare in this cohort. Similar studies have reported 
much higher rates of traditional medicine use among victims of 
snakebites [18]. It is possible that the patients in this study 
underreported use of traditional or herbal therapies due to fear of 
repercussions from health care providers [19]. However, the 
findings might also suggest a degree of confidence in allopathic 
medical care for this indication.  
  
The most common clinical features resulting from snakebites in our 
study were related to local effects such as pain, swelling, and 
bleeding. Bleeding was present in 51% of the cases and prolonged 
clotting was 66.0%. These findings suggest a high proportion of 
cases were likely attributable to vipers, a commonest venomous 
snakebite in Ghana (16) with hemotoxic venom. Bleeding is usually 
caused by combined effects of procoagulants contained in the 
hemotoxic venom of some snake species, which activates factors II 
and X as well as rhexic hemorrhagins that directly damage the 
capacitance vessel endothelial basement membrane, leading to 
disseminated intravascular coagulopathy [20]. Coagulopathic 
features range from local bleeding or bleeding from nostrils, mouth 
and wound site, some of which were experienced by our study 
participants, and 66.0% of patients showed a prolonged clotting 
time as a result of envenomation. The whole blood clotting time test 
is a simple, easy and reliable test to determine the degree of 
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coagulopathy as well as to monitor the effectiveness of anti-venom 
in restoring blood coagulability [21]. The clotting time is considered 
prolonged or positive when whole blood in a test tube fails to clot at 
room temperature after 20 minutes.  
  
Snake anti-venom in this study was administered in about 77% of 
cases, much higher than reported in other, similar studies [22,23]. 
This finding might reflect the combined effects of various efforts of 
the study hospitals to procure snake anti-venom from 
pharmaceutical companies and local chemical sellers outside the 
usual supply and procurement systems. Snake anti-venom supplied 
from outside the routine system cost an equivalent of US$ 35.00 per 
vial as compared with free distribution from the routine health 
system. These extra costs are often too high for patients. In 
addition, the therapeutic effect of these anti-venoms is sometimes 
doubtful as maintenance of the cold-chain cannot be fully 
guaranteed in the light of unreliable power supply in these settings. 
The snake anti-venom used in our study consisted of a lyophilized 
polyvalent enzyme-refined equine immunoglobulin imported from 
India. It is produced by Vins Bioproduct limited, and targeted 
against the venom of four major snake species: the common krait, 
the Indian cobra (Naja naja), the Russell’s viper, and the Saw-scaled 
viper [24]. This anti-venom’s therapeutic effectiveness against 
African snake species, which may be antigenically distinct from 
Indian snakes, has not yet been verified although other anti-venoms 
from India showed poor performance against African snakes [5,16]. 
Over 84% of the victims received between 2-10 vials of antiserum 
with an average of 4.5vials per victim, a further demonstration of 
poor results associated with the anti-venom against snakes in this 
setting. Guideline for administration of anti-venom as well as 
repeated doses was based on the presence of evidence of 
envenomation such as prolonged clotting time, bleeding from any 
part of the body apart from site of bite, evidence of shock, central 
nervous system manifestations or any prostration following 
snakebite. Although documentation of adverse reaction to anti-
venom was poor, massive use of corticosteroids and antihistamines 
in this study could possibly be due to these reactions or in their 
anticipation from previous experience. However, steroids and 
antihistamines have no documented value as a preventive measure 
to reduce the incidence of anaphylaxis associated with anti-venom 
use [25].  
  
Administration of effective snake anti-venom remains the gold 
standard in treating life-threatening reactions to snakebites. Unlike 
the weight-based dosing of many other medications, amount of 
anti-venoms is usually dependent on the type of snake and the 
amount of venom injected through the bite [15] as well as the 
patient´s clinical evolution, abnormal findings, response to initial 
anti-venom given and patient co-morbidities. Anti-venom should be 
administered as early as possible during the course of the 
envenomation, once the activity of venom in the victim’s body has 
been clinically proven and in order to prevent further deterioration 
of the patient’s condition [20]. Over 96% of respondents were given 
prophylactic antibiotics probably due to lack of guidelines, which 
could lead to wasteful use of antibiotics with potential side effects 
and development of drug resistance. Prophylactic antibiotics have 
no documented benefits after snakebite, except for suspicion of 
secondary infection [13]. 74.2% of the patients were given anti-
tetanus. This is similar to observations made by Omogbai et al [26]. 
Most snakes carry pathogenic organisms, such as Clostridium tetani, 
in their mouths as part of normal oral flora, and snakebites usually 
cause punctured wounds [27]. Anti-tetatus prophylaxis should 
therefore routinely be given after assessing the status of 
immunization. Blood products, such as packed red blood cells, 
should only be given for specific indications such as severe 
haemorrhage or anaemia. Where resources are available transfusion 
of fresh frozen plasma or Vitamin K administration has been 
recommended for uncontrolled bleeding when prothrombin time( 
PT) and partial thromboplastin time(PTT are prolonged [28].  
  
This study has limitations which affects its interpretation. First, data 
collection was facility-based. With this, our study cannot provide 
concise estimates on the incidence of snake bites not reported to 
the hospital, or about victims who sought care outside the formal 
health care system. The incidence of snake-bites observed by us is 
therefore likely an underestimate of the true incidence in this 
population. To estimate the population-based incidence of 
snakebites, a household survey would have been the more 
appropriate method. However, this approach would have been too 
time consuming and resource-intensive given the geography of the 
Bole and Kintampo districts. Our facility-based incidence estimates 
still illustrate an important piece of the epidemiology of snake-bites 
in health facilities in rural Sub-Saharan Africa and thus provides 
useful information for health planning purposes related to the 
appropriate distribution and supply of anti-venom, especially during 
those seasons when there is an increased risk.  
  
Secondly, in a good number of cases the snakes were not seen and 
even in cases where a snake was seen, color description was 
proffered and no effort was made to identify them for lack of 
capacity. Proper identification of snakes would have provided good 
epidemiological information on the type of snakes in the geographic 
area which could improve the management of snakebites in the 
region. Lastly, missing information on some of the variables in our 
data could result in misclassification of variables. However this 
missing information occurred randomly and therefore its effect will 
be minimal.  
  
  
Conclusion 
 
In conclusion, more men report cases of snakebites than women in 
the two districts studied and tend to occur in the months with 
higher Agricultural activities. The bites are mostly in the lower limbs. 
There was a routine use of antibiotics, corticosteroids and 
antihistamines as prophylaxis due to lack of guidelines in the 
management of snakebites. Also, administration of anti-venom 
produced for Indian snakes which already showed poor performance 
in this setting could lead to prolonged hospitalization. We 
recommend provision of protocols and their strict adherence in the 
management of snakebites as a means of limiting unwarranted use 
of antibiotics and steroids. We further recommend evaluation of all 
anti-venoms imported for management of snakebite to ascertain 
their effectiveness so as to reduce morbidity and mortality 
associated with snakebites in this region.  
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Table 1: characteristics of victims and circumstances of snakebite exposure 
Characteristics Number of Snakebites 
N=163 
Percentages 
Envenomation during bite     
       Yes 125 76.7 
        No 27 16.6 
          Missing 11 6.7 
Age group     
       0-19 76 46.6 
       20-59 74 44.8 
       60+ 7 4.3 
       Missing 7 4.3 
Sex     
        Male 101 62.0 
        Female 61 37.4 
        Missing      1 0.6 
Site     
        Bole 82 50.3 
        Kintampo 81 49.7 
Educational status     
       None 87 53.4 
      Primary 61 37.4 
      Secondary 9 5.5 
      postsecondary 1 0.6 
      Missing 5 3.1 
Occupation     
       Farmer 68 41.7 
       Student 47 28.8 
       Child (unemployed) 8 4.9 
      Other 19 11.7 
      Missing 21 12.9 
Valid National health insurance     
       Insured 74 45.5 
       Non-insured 76 46.6 
       Missing 13 8.0 
Snake seen     
      Yes 95 58.3 
      No 59 36.2 
      Missing 9 5.5 
Cumulative incidence of snakebites in the two hospitals was 83/100,000 population 
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Table 2: distribution of victims by snakebite exposure characteristics 
Characteristics Number of snake bites 
N=163 
Percentage 
Circumstances   
      Walking 17 10.4 
      Farm-related 82 50.3 
      In-house activity 22 13.5 
      Out-door 26 16.0 
      Missing 16 9.8 
Time of bite   
   Day time 51 31.3 
    Night time 108 66.3 
    Missing 4 2.4 
Time from bite to presentation   
       1-3hrs 78 47.8 
       4-12hrs 80 49.1 
       >24hrs 5 3.1 
Site of bite   
       Upper limb 23 14.1 
      Lower limb 118 72.4 
      Trunk 7 4.3 
      Missing 15 9.2 
Pre-hospital treatment   
       Tourniquet 6 3.4 
      Local incision 16 9.8 
       Herbs applied 35 21.5 
       Black stone 5 3.1 
      Wound cleaned and covered 10 6.2 
      No pre-hospital treatment 91 55.8 
Snakes seen by victims were described in colors and local names thus making classification 
difficult 
 
 
 
 
 
 
 
 
Table 3: clinical signs and symptoms of snakebites presenting to the two 
hospitals* 
Symptoms/signs Frequency Percentage 
 Local pain 151 92.6 
 Local swelling 137 84.1 
 Local bleeding 83 50.9 
 Local redness 2 1.2 
 Haematemesis 20 12.3 
 Diarrhoea 2 1.2 
 Oedema 44 27.0 
 Prolonged clotting time  107 66.0 
 Haematuria 2 1.2 
 Other bleeding 11 6.7 
 Hypotension 38 23.5 
 Dizziness 20 12.3 
 Others 34 20.9 
Prolonged clotting time occurs when whole blood in a test tube does not 
clot at room temperature after 20 minutes; *Multiple responses 
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Table 4: management and outcome of snakebites in the two district 
hospitals 
Treatment type Frequency Percentage 
Number of cases receiving+  anti-
venom 
    
Yes 125 76.7 
No 37 22.7 
Missing 1` 0.6 
Dose of anti-venom*     
1 18 14.4 
2-5 76 60.8 
≥6 31 24.8 
Source of antivenom*     
Free supply from GHS 59 47.2 
Bought from hospital  32 25.6 
Bought from town 29 23.2 
Missing 5 4.0 
Antihistamine†     
Yes 95 58.8 
No 62 38.0 
Missing 6 3.7 
Corticosteroids†     
Yes 149 91.4 
No 14 8.6 
Antitetanus†     
Yes 121 74.2 
No 42 25.8 
Antibiotics†     
Yes 157 96.3 
No 6 3.7 
Blood transfusion†     
Yes 17 10.4 
No 138 84.7 
Missing 8 4.9 
Vitamin k†     
 Yes 16 9.8 
 No 136 83.4 
 Missing 11 6.8 
Type of hospital care†     
In-patient 160 98.2 
Outpatient 3 1.8 
Outcome†     
Treated and discharged 127 78.4 
Discharged against medical       advice 7 4.4 
 Referred to another hospital 28 17.28 
 Missing 1 0.6 
Average duration of hospital stay was 4.4 days for both sexes 
*Total=Number of cases receiving anti-venom (125) 
†Total Total number of cases (163) 
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Figure 1: a map of Ghana showing Kintampo north and Bole districts 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
